Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Verrica Pharmaceuticals Inc. before investing.

In this article, we go over a few key elements for understanding Verrica Pharmaceuticals Inc.’s stock price such as:

• Verrica Pharmaceuticals Inc.’s current stock price and volume
• Why Verrica Pharmaceuticals Inc.’s stock price changed recently
• Upgrades and downgrades for VRCA from analysts
• VRCA’s stock price momentum as measured by its relative strength

About Verrica Pharmaceuticals Inc. (VRCA)

Before we jump into Verrica Pharmaceuticals Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Want to learn more about Verrica Pharmaceuticals Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Verrica Pharmaceuticals Inc..

Verrica Pharmaceuticals Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Verrica Pharmaceuticals Inc.’s stock price was $5.220.

Verrica Pharmaceuticals Inc. is down 0.76% from its previous closing price of $5.260.

During the last market session, Verrica Pharmaceuticals Inc.’s stock traded between $5.210 and $5.550. Currently, there are approximately 21.31 million shares outstanding for Verrica Pharmaceuticals Inc..

Verrica Pharmaceuticals Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Verrica Pharmaceuticals Inc. Stock Price History

Verrica Pharmaceuticals Inc.’s (VRCA) price is currently down 14.71% so far this month.

During the month of July, Verrica Pharmaceuticals Inc.’s stock price has reached a high of $6.790 and a low of $5.000.

Over the last year, Verrica Pharmaceuticals Inc. has hit prices as high as $9.821 and as low as $3.280. Year to date, Verrica Pharmaceuticals Inc.’s stock is down 37.18%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Verrica Pharmaceuticals Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there was 1 analyst who downgraded Verrica Pharmaceuticals Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Verrica Pharmaceuticals Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Verrica Pharmaceuticals Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Verrica Pharmaceuticals Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Verrica Pharmaceuticals Inc. (VRCA) by visiting AAII Stock Evaluator.

Relative Price Strength of Verrica Pharmaceuticals Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Verrica Pharmaceuticals Inc. has a weighted four-quarter relative price strength of -0.33%, which translates to a Momentum Score of 50 and is considered to be Average.

Want to learn more about how Verrica Pharmaceuticals Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Verrica Pharmaceuticals Inc. Stock Price: Bottom Line

As of July 31, 2026, Verrica Pharmaceuticals Inc.’s stock price is $5.220, which is down 0.76% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Verrica Pharmaceuticals Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.